EP Patent

EP1874273A2 — Gastroresistant pharmaceutical formulations containing rifaximin

Assigned to Alfa Wasserman SpA · Expires 2008-01-09 · 18y expired

What this patent protects

The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use…

USPTO Abstract

The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP1874273A2
Jurisdiction
EP
Classification
—
Expires
2008-01-09
Drug substance claim
No
Drug product claim
No
Assignee
Alfa Wasserman SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.